Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma

Bibliography

• Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med 2006;355:2226-35
   PubMed Web of Science ®Google Scholar
• Platts-Mills T, de Weck AL, Aalberse R, et al. Dust mite allergens and asthma—A worldwide problem. J Allergy Clin Immunol 1989;83(2 Pt 1):416-27
   PubMed Web of Science ®Google Scholar
• Lodge CJ, Lowe AJ, Gurrin LC, et al. House dust mite sensitization in toddlers predicts current wheeze at age 12 years. J Allergy Clin Immunol 2011;128(4):782-8
   PubMed Web of Science ®Google Scholar
• Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008;372(9643):1049-57
   PubMed Web of Science ®Google Scholar
• Sheikh A, Hurwitz B, Nurmatov U, van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev 2010(7):CD001563
   Google Scholar
• Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev 2008(2):CD001187
   Google Scholar
• Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102(4 Pt 1):558-62
   PubMed Web of Science ®Google Scholar
• Bacharier LB, Boner A, Carlsen KH, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008;63:5-34
   PubMed Web of Science ®Google Scholar
• Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011;11(6):586-93
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010;4(8):CD001186
   Google Scholar
• Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;24(1):CD001936
   Google Scholar
• Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J 2009;2(11):233-81
   Google Scholar
• Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010(12):CD002893
   PubMed Web of Science ®Google Scholar
• Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009;64(11):1570-9
   PubMed Web of Science ®Google Scholar
• Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006;61(10):1162-72
   PubMed Web of Science ®Google Scholar
• Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990;18(5):277-84
   PubMed Web of Science ®Google Scholar
• Hirsch T, Sähn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997;8(1):21-7
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629-32
   PubMed Web of Science ®Google Scholar
• Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;55:249-60
   Google Scholar
• Guez S, Vatrinet C, Fadel R, André C. House dust mite sublingual swallow immunotherapy (SLIT) in perennial rhinitis: a double blind, placebo-controlled study. Allergy 2000;55:369-75
   PubMed Web of Science ®Google Scholar
• Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double- blind, placebo-controlled study. Allergy 2000;55:842-9
   PubMed Web of Science ®Google Scholar
• Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001;32:49-55
   PubMed Web of Science ®Google Scholar
• Ippoliti F, De Santis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003;14(3):216-21
   PubMed Web of Science ®Google Scholar
• Tonnel AB, Scherpereel A, Douay B, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004;59(5):491-7
   PubMed Web of Science ®Google Scholar
• Marcucci F, Sensi L, Di Cara G, et al. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol 2005;16(6):519-26
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Pasquali M, Ariano R, et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006;61(7):849-54
   PubMed Web of Science ®Google Scholar
• Niu CK, Chen WY, Huang JL, et al. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo- controlled study in Taiwan. Respir Med 2006;100:1374-83
   PubMed Web of Science ®Google Scholar
• Lue KH, Lin YH, Sun HL, et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006;17:408-15
   PubMed Web of Science ®Google Scholar
• Pham-Thi N, Scheinmann P, Fadel R, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007;18:47-57
   PubMed Web of Science ®Google Scholar
• O'Hehir RE, Gardner LM, de Leon MP, et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009;180(10):936-47
   PubMed Web of Science ®Google Scholar
• Yonekura S, Okamoto Y, Sakurai D, et al. Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children. Allergol Int 2010;59(4):381-8
   PubMedGoogle Scholar
• Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 2011;127(4):974-81
   PubMed Web of Science ®Google Scholar
• de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol 2012;23(2):150-8
   PubMed Web of Science ®Google Scholar
• Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012;157(3):288-98
   PubMed Web of Science ®Google Scholar
• Bozek A, Ignasiak B, Filipowska B, Jarzab J. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy 2013;43(2):242-8
   PubMed Web of Science ®Google Scholar
• Ameal A, Vega-Chicote JM, Fernández S, et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005;60(9):1178-83
   PubMed Web of Science ®Google Scholar
• García-Robaina JC, Sánchez I, de la Torre F, et al. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006;118(5):1026-32
   PubMed Web of Science ®Google Scholar
• Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006;61(7):843-8
   PubMed Web of Science ®Google Scholar
• Wang H, Lin X, Hao C, et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006;61(2):191-7
   PubMed Web of Science ®Google Scholar
• Blumberga G, Groes L, Dahl R. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma. Allergy 2011;66(2):178-85
   PubMed Web of Science ®Google Scholar
• Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011;66(6):740-52
   PubMed Web of Science ®Google Scholar
• Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008;63(3):374
   PubMed Web of Science ®Google Scholar
• Calderón MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67(3):302-11
   PubMed Web of Science ®Google Scholar
• Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006;61(Suppl 82):1-20
   PubMed Web of Science ®Google Scholar
• Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010;125:569-74
   PubMed Web of Science ®Google Scholar
• Winther L, Arnved J, Malling HJ, et al. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy 2006;36(3):254-60
   PubMed Web of Science ®Google Scholar
• Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010;40:922-32
   PubMed Web of Science ®Google Scholar
• Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergen specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 2011;128:808-15
   PubMed Web of Science ®Google Scholar
• Piazza I, Bizzaro N. Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus. Ann Allergy 1993;71(5):461-9
   PubMedGoogle Scholar
• Mungan D, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: a placebo controlled study. Ann Allergy Asthma Immunol 1999;82:485-90
   PubMed Web of Science ®Google Scholar
• Shamji MH, Ljørring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012;67(2):217-26
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999;341:468-75
   PubMed Web of Science ®Google Scholar
• Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51:430-3
   PubMed Web of Science ®Google Scholar
• Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997;100:293-300
   PubMed Web of Science ®Google Scholar
• Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99(4):450-3
   PubMed Web of Science ®Google Scholar
• Cools M, Van Bever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy 2000;55(1):69-73
   PubMed Web of Science ®Google Scholar
• Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31(9):1392-7
   PubMed Web of Science ®Google Scholar
• Tabar AI, Arroabarren E, Echechipía S, et al. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011;127(1):57-63
   PubMed Web of Science ®Google Scholar
• Stelmach I, Sobocińska A, Majak P, et al. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol 2012;109(4):274-8
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129(3):717-25
   PubMed Web of Science ®Google Scholar
• Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33(2):206-10
   PubMed Web of Science ®Google Scholar
• Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126(5):969-75
   PubMed Web of Science ®Google Scholar
• Robinson DS, Larché M, Durham SR. Tregs and allergic disease. J Clin Invest 2004;114(10):1389-97
   PubMed Web of Science ®Google Scholar
• Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008;121:1120-5
   PubMed Web of Science ®Google Scholar
• Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64-71
   PubMed Web of Science ®Google Scholar
• Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252-9
   PubMed Web of Science ®Google Scholar
• Pilette C, Nouri-Aria KT, Jacobson MR, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007;178:4658-66
   PubMed Web of Science ®Google Scholar
• Meiler F, Zumkehr J, Klunker S, et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008;205:2887-98
   PubMed Web of Science ®Google Scholar
• Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008;121:1467-72
   PubMed Web of Science ®Google Scholar
• Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010;40:598-606
   PubMed Web of Science ®Google Scholar
• Dreborg S, Lee TH, Kay AB, Durham SR. Immunotherapy is allergen-specific: a double-blind trial of mite or timothy extract in mite and grass dual-allergic patients. Int Arch Allergy Immunol 2012;158(1):63-70
   PubMed Web of Science ®Google Scholar
• Linneberg A, Jacobsen RK, Jespersen L, Abildstrøm SZ. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 2012;129(2):413-19
   PubMed Web of Science ®Google Scholar
• Baron-Bodo V, Batard T, Nguyen H, et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clin Exp Allergy 2012;42(10):1510-18
   PubMed Web of Science ®Google Scholar
• Bahceciler NN, Arikan C, Taylor A, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005;136(3):287-94
   PubMed Web of Science ®Google Scholar
• Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-g- and interleukin-10-production. Clin Exp Allergy 2006;36:261-72
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Fenoglio D, Cirillo I, et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005;95:38-44
   PubMed Web of Science ®Google Scholar
• Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-13
   PubMed Web of Science ®Google Scholar
• Swamy RS, Reshamwala N, Hunter T, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol 2012;130:215-24
   PubMed Web of Science ®Google Scholar
• Gardner LM, Thien FC, Douglass JA, et al. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy 2004;34(8):1209-19
   PubMed Web of Science ®Google Scholar
• Lou W, Wang C, Wang Y, et al. Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. Pediatr Allergy Immunol 2012;23(2):140-9
   PubMedGoogle Scholar